Contents:

EXECUTIVE SUMMARY Key Market Events in April 2002 STRUCTURE OF UPDATE ANALYSIS OF KEY DEVELOPMENTS IN APRIL 2002 COMPANY HEADLINES Interpretation Software for TRUGENE HIV Resistance Test Approved by FDA Trimeris Share Price Rockets After Clinical Trial Update Phase I SBIR Grant Awarded to Consensus Pharmaceuticals for HIV Drug Discovery Roche Receives Approval for HIV Diagnostic Test in Italy RESEARCH AND DEVELOPMENT HEADLINES Protease Inhibitors Show Limited Transplacental Passage HAART Switching Often Due to Toxicities Maintenance of Crixivan Serum Trough Levels Minimizes Toxicity Viracept Required to Maintain Plasma Concentrations of saquinavir in HIV-positive Children Novel Assay Shows Mitochondrial DNA Depletion in NRTI-Treated Patients New Vaccine Technology Shows Promise in HIV DNA Vaccine Proves Hopeful Against SIV NIH Grants ProdiGene Funds to Conduct Research into HIV and SIV Vaccines Initial Clinical Trial Results Indicate Potential for IAVI HIV Vaccines Controversial HIV Immune Based Therapy Trial Expanded New HIV Drug to be Developed at the Parker Hughes Institute DISEASE SPECIFIC HEADLINES Higher Incidence of HIV Infection in Female Intravenous Drug Users Could HAART Immune Restoration Make Fungal Prophylaxis Redundant? CDC Recommends Voluntary HIV Testing WHO Includes HIV Drugs in Essential Drugs List Potential for TB and HIV Health Crisis Across Europe Immune Activation by Measles Co-infection Suppresses HIV Advantages to Deferring HAART Therapy in HIV/TB Co-infected Patients Complement Activation in HIV Dementia Confirmed Inadequate Viral Load Monitoring in HIV-Infected Drug Users EMERGING MARKETS HEADLINES Angola to Provide HIV Drugs to Population Mining Companies Take on HIV Alone China HIV Estimates Increase by Quarter Million in Just One Year APPENDIX Datamonitor's Infectious Disease Business Unit Research Background Contacts and Further Reading